BETHESDA, Md., March 30 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the year ended December 31, 2008.
Recent Company Highlights
"The next few months will be an exciting time for Spherix and its shareholders," stated Dr. Claire L. Kruger, CEO of Spherix. "The Company anticipates sharing interim data in the fall from its ongoing Phase 3 clinical trial investigating the efficacy of Naturlose as a novel treatment for Type 2 diabetes. I am pleased to report that Spherix will be holding its first earnings webcast on April 2, during which we will provide our shareholders and other interested parties with additional information and updates on both the Biospherics and Spherix Consulting subsidiaries."
Financial Results for the Year Ended 2008
|SOURCE Spherix Incorporated|
Copyright©2009 PR Newswire.
All rights reserved